Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Simmerafil (TPN171H): A Comprehensive Report on its Pharmacology and Clinical Development
1. Executive Summary
Simmerafil, also identified by its investigational code TPN171H, is an orally bioavailable small molecule that functions as a potent and selective phosphodiesterase type 5 (PDE5) inhibitor.[1] The compound is currently in advanced stages of clinical development, primarily targeting two distinct therapeutic indications: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Key entities spearheading its development include Vigonvita Life Sciences and the Shanghai Institute of Materia Medica.[2] Clinical investigations for ED have progressed to Phase III, with a New Drug Application (NDA) reportedly under review in China, while for PAH, Simmerafil (TPN171H) has completed Phase IIa clinical trials, demonstrating encouraging effects on pulmonary hemodynamics.[2]
It is imperative to address a notable ambiguity concerning the nomenclature "Simmerafil." The vast majority of detailed scientific information available, including specific chemical identifiers such as CAS number 1229018-87-4 and PubChem CID 136197286, along with extensive clinical trial data, unequivocally pertains to Simmerafil (TPN171H) as a selective PDE5 inhibitor.[1] However, two research snippets [8] describe a compound also named "Simmerafil" but characterize it as a Janus Kinase (JAK) inhibitor intended for the treatment of autoimmune conditions like rheumatoid arthritis and psoriasis. These latter descriptions lack the specific chemical identifiers and depth of corroborating clinical data associated with TPN171H. Consequently, this report will focus exclusively on Simmerafil (TPN171H), the PDE5 inhibitor, for which substantial and consistent evidence is provided. This discrepancy highlights potential issues in early-stage drug nomenclature or database inconsistencies, emphasizing the value of precise investigational codes.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/03/08 | Phase 3 | Recruiting | Vigonvita Life Sciences | ||
2023/10/19 | Phase 1 | Completed | Vigonvita Life Sciences | ||
2023/10/19 | Phase 1 | Completed | Vigonvita Life Sciences | ||
2023/07/17 | Phase 1 | Completed | Vigonvita Life Sciences | ||
2022/01/11 | Phase 1 | Completed | Vigonvita Life Sciences | ||
2020/07/23 | Phase 2 | Completed | Vigonvita Life Sciences | ||
2020/07/21 | Phase 2 | Completed | Vigonvita Life Sciences |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.